Georgia Pharmacy Board Actions - January 2026

The Georgia Board of Pharmacy has issued its January 2026 Public Board Actions List. This list details enforcement actions taken against licensees, including the summary suspension of a facility's license and the lifting of a pharmacist's suspension. Specific licensee names and license numbers are provided for each action.

Georgia Pharmacy Board Actions - February 2026

The Georgia Board of Pharmacy has issued a list of actions taken in February 2026. These actions include a voluntary surrender for a technician and a consent order for a facility, Xttrium Laboratories, Inc. Specific details on the nature of the consent order and surrender are pending further documentation.

GA Board of Pharmacy Actions - January 2025

The Georgia Board of Pharmacy has revoked the registration of Yental Breanna Alford (PHTC051190) in its January 2025 public actions list. This action pertains to a pharmacy technician.

GA Board of Pharmacy Actions - February 2025

The Georgia Board of Pharmacy has issued a list of actions taken in February 2025. These actions include a voluntary cease and desist order for Steri-Tek PHWH004241 and a consent order for S2 Medical Supply, LLC (PHDME000685). Specific details on the nature of violations or penalties are not provided in this summary.

Georgia Board of Pharmacy Consent Orders and Revoked Registrations

The Georgia Board of Pharmacy has issued consent orders for Musely Compounding Pharmacy East LLC and Cornerstone Medical, Inc. Additionally, registrations for technicians Amira Jayde Brooks and Cythnia Elaine Brannon have been revoked.

CITA Designated as Significant Benchmark

The Danish Financial Supervisory Authority (DFSA) has designated the CITA benchmark as significant under Article 24(7) of the EU Benchmarks Regulation. This designation means CITA remains subject to the regulation and supervision by the DFSA, impacting its administration and use in financial markets.

CIBOR Notified as Significant Benchmark Under EU Benchmarks Regulation

The Danish Financial Supervisory Authority announced that CIBOR has been notified as a significant benchmark under the EU Benchmarks Regulation due to its use in financial instruments exceeding EUR 50 billion. This notification confirms CIBOR's continued subject to the regulation and supervision by the Danish authority following recent amendments to the BMR.

DFSA Fee Collection Rules for Financial Companies

The Danish Financial Supervisory Authority (DFSA) is implementing new fee collection rules effective from 2025. These changes will affect securities broker holding companies, financial advisers, mortgage credit intermediaries, insurance intermediaries, investment advisers, and companies advising consumers on financial products. The rules clarify legal references and extend fee obligations to new entities.

Danish Banks Meet Capital Requirements in EU Stress Test

The Danish Financial Supervisory Authority announced the results of the EU-wide stress test for Danish banks. While capital ratios were significantly depleted, the participating institutions, including Danske Bank, Nykredit, and Jyske Bank, generally met capital requirements under an adverse scenario, showing improvement from previous tests.

Denmark DFSA Official Nominated for EU AMLA Management Role

The Danish Financial Supervisory Authority announced that Rikke-Louise Ørum Petersen has been nominated for a top management role in the EU's new Anti-Money Laundering Authority (AMLA). The Council of Ministers is expected to make a final decision on May 22, 2025. This nomination signifies a significant development in the EU's efforts to strengthen anti-money laundering and counter-terrorist financing efforts.